FDA
-
-
-
-
-
-
-
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
-
-
-
-
-
-
-
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
-
-
-
-
-
-
-
Sol-Gel Technologies Announces Management Realignment
-
-
-
-
-
-
-
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
-
-
-
-
-
-
-
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
-
-
-
-
-
-
-
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
-
329,886 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

